Evogliptin, a Dipeptidyl Peptidase-4 Inhibitor, Attenuates Renal Fibrosis Caused by Unilateral Ureteral Obstruction in Mice
Diabetes & Metabolism Journal
;
: 186-192, 2020.
Article
in English
| WPRIM
| ID: wpr-811137
ABSTRACT
Renal fibrosis is considered to be the final common outcome of chronic kidney disease. Dipeptidyl peptidase-4 (DPP-4) inhibitors have demonstrated protective effects against diabetic kidney disease. However, the anti-fibrotic effect of evogliptin, a DPP-4 inhibitor, has not been studied. Here, we report the beneficial effects of evogliptin on unilateral ureteral obstruction (UUO)-induced renal fibrosis in mice. Evogliptin attenuated UUO-induced renal atrophy and tubulointerstitial fibrosis. Immunohistochemistry and Western blotting demonstrated that evogliptin treatment inhibits pro-fibrotic gene expressions and extracellular matrix production. In vitro findings showed that the beneficial effects of evogliptin on renal fibrosis are mediated by inhibition of the transforming growth factor-β/Smad3 signaling pathway. The present study demonstrates that evogliptin is protective against UUO-induced renal fibrosis, suggesting that its clinical applications could extend to the treatment of kidney disease of non-diabetic origin.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Atrophy
/
Ureter
/
Ureteral Obstruction
/
In Vitro Techniques
/
Fibrosis
/
Immunohistochemistry
/
Gene Expression
/
Blotting, Western
/
Transforming Growth Factor beta
/
Diabetic Nephropathies
Limits:
Animals
Language:
English
Journal:
Diabetes & Metabolism Journal
Year:
2020
Type:
Article
Similar
MEDLINE
...
LILACS
LIS